Publications by authors named "Thomas Appl"

Claim this Profile
S
SARS-CoV-2 convalescent plasma for the controlled clinical trial "COVIC-19": Experience from collection of very high-titer plasma from superimmunized individuals.
Simone Hoffmann, Alina Seidel, Carolin Ludwig, Christiane Vieweg, Rebecca Müller, Thomas Appl

Transfusion· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial.
Maxime Desmarets, Simone Hoffmann, Charline Vauchy, Bart J A Rijnders, Eric Toussirot, Thomas Appl

BMJ Open· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Plasma for the Treatment of COVID-19: Lessons Learned so far.
Hubert Schrezenmeier, Simone Hoffmann, Henrike Hofmann, Thomas Appl, Bernd Jahrsdörfer

Hamostaseologie· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients.
Sixten Körper, Beate Grüner, Daniel Zickler, Thomas Wiesmann, Patrick Wuchter, Thomas Appl

J Clin Invest· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine levels associated with favorable clinical outcome in the CAPSID randomized trial of convalescent plasma in patients with severe COVID-19.
Sixten Körper, Eva Vanessa Schrezenmeier, Hector Rincon-Arevalo, Beate Grüner, Daniel Zickler, Thomas Appl

Front Immunol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19.
Sixten Körper, Manfred Weiss, Daniel Zickler, Thomas Wiesmann, Kai Zacharowski, Thomas Appl

J Clin Invest· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies.
Sixten Körper, Bernd Jahrsdörfer, Victor M Corman, Jan Pilch, Patrick Wuchter, Thomas Appl

Transfus Med Hemother· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting mutant huntingtin for the development of disease-modifying therapy.
Thomas Appl, Linda Kaltenbach, Donald C Lo, Georg C Terstappen

Drug Discov Today· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spontaneous in vitro transformation of adult neural precursors into stem-like cancer cells.
Florian A Siebzehnrubl, Ina Jeske, Dorit Müller, Rolf Buslei, Roland Coras, Thomas Appl

Brain Pathol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of glutaminyl cyclase prevents pGlu-Abeta formation after intracortical/hippocampal microinjection in vivo/in situ.
Stephan Schilling, Thomas Appl, Torsten Hoffmann, Holger Cynis, Katrin Schulz

J Neurochem· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis